» Articles » PMID: 25452562

Ex Vivo-expanded but Not in Vitro-induced Human Regulatory T Cells Are Candidates for Cell Therapy in Autoimmune Diseases Thanks to Stable Demethylation of the FOXP3 Regulatory T Cell-specific Demethylated Region

Overview
Journal J Immunol
Date 2014 Dec 3
PMID 25452562
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

Regulatory T cell (Treg) therapy is a promising approach for transplant rejection and severe autoimmunity. Unfortunately, clinically meaningful Treg numbers can be obtained only upon in vitro culture. Functional stability of human expanded (e)Tregs and induced (i)Tregs has not been thoroughly addressed for all proposed protocols, hindering clinical translation. We undertook a systematic comparison of eTregs and iTregs to recommend the most suitable for clinical implementation, and then tested their effectiveness and feasibility in rheumatoid arthritis (RA). Regardless of the treatment, iTregs acquired suppressive function and FOXP3 expression, but lost them upon secondary restimulation in the absence of differentiation factors, which mimics in vivo reactivation. In contrast, eTregs expanded in the presence of rapamycin (rapa) retained their regulatory properties and FOXP3 demethylation upon restimulation with no stabilizing agent. FOXP3 demethylation predicted Treg functional stability upon secondary TCR engagement. Rapa eTregs suppressed conventional T cell proliferation via both surface (CTLA-4) and secreted (IL-10, TGF-β, and IL-35) mediators, similarly to ex vivo Tregs. Importantly, Treg expansion with rapa from RA patients produced functionally stable Tregs with yields comparable to healthy donors. Moreover, rapa eTregs from RA patients were resistant to suppression reversal by the proinflammatory cytokine TNF-α, and were more efficient in suppressing synovial conventional T cell proliferation compared with their ex vivo counterparts, suggesting that rapa improves both Treg function and stability. In conclusion, our data indicate Treg expansion with rapa as the protocol of choice for clinical application in rheumatological settings, with assessment of FOXP3 demethylation as a necessary quality control step.

Citing Articles

The Effect of Boric Acid and Calcium Fructoborate on T Helper Cell Differentiation by Influencing Foxp3 and Ror-γt in Rheumatoid Arthritis and Systemic Lupus Erythematosus.

Yapar R, Gunduz O, Kurt F, Korkmaz M Biol Trace Elem Res. 2024; .

PMID: 39446208 DOI: 10.1007/s12011-024-04425-9.


Methylation of T and B Lymphocytes in Autoimmune Rheumatic Diseases.

Deng T, Wang Z, Geng Q, Wang Z, Jiao Y, Diao W Clin Rev Allergy Immunol. 2024; 66(3):401-422.

PMID: 39207646 DOI: 10.1007/s12016-024-09003-4.


Chimeric Antigen Receptor (CAR)-Based Cell Therapy for Type 1 Diabetes Mellitus (T1DM); Current Progress and Future Approaches.

Mohammadi V, Jahani Maleki A, Nazari M, Siahmansouri A, Moradi A, Elahi R Stem Cell Rev Rep. 2023; 20(3):585-600.

PMID: 38153634 DOI: 10.1007/s12015-023-10668-1.


Changes in the gut microbiota of NOD mice in response to an oral Salmonella-based vaccine against type 1 diabetes.

Cobb J, Soliman S, Retuerto M, Quijano J, Orr C, Ghannoum M PLoS One. 2023; 18(5):e0285905.

PMID: 37224176 PMC: 10208495. DOI: 10.1371/journal.pone.0285905.


Adoptive T therapy with metabolic intervention via perforated microneedles ameliorates psoriasis syndrome.

Zhang W, Chen Y, Zhao Z, Zheng H, Wang S, Liao Z Sci Adv. 2023; 9(20):eadg6007.

PMID: 37196084 PMC: 11803960. DOI: 10.1126/sciadv.adg6007.


References
1.
Battaglia M, Stabilini A, Tresoldi E . Expanding human T regulatory cells with the mTOR-inhibitor rapamycin. Methods Mol Biol. 2011; 821:279-93. DOI: 10.1007/978-1-61779-430-8_17. View

2.
Kim H, Leonard W . CREB/ATF-dependent T cell receptor-induced FoxP3 gene expression: a role for DNA methylation. J Exp Med. 2007; 204(7):1543-51. PMC: 2118651. DOI: 10.1084/jem.20070109. View

3.
Polansky J, Schreiber L, Thelemann C, Ludwig L, Kruger M, Baumgrass R . Methylation matters: binding of Ets-1 to the demethylated Foxp3 gene contributes to the stabilization of Foxp3 expression in regulatory T cells. J Mol Med (Berl). 2010; 88(10):1029-40. PMC: 2943068. DOI: 10.1007/s00109-010-0642-1. View

4.
Scotta C, Esposito M, Fazekasova H, Fanelli G, Edozie F, Ali N . Differential effects of rapamycin and retinoic acid on expansion, stability and suppressive qualities of human CD4(+)CD25(+)FOXP3(+) T regulatory cell subpopulations. Haematologica. 2012; 98(8):1291-9. PMC: 3729911. DOI: 10.3324/haematol.2012.074088. View

5.
Lal G, Zhang N, van der Touw W, Ding Y, Ju W, Bottinger E . Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J Immunol. 2008; 182(1):259-73. PMC: 3731994. DOI: 10.4049/jimmunol.182.1.259. View